Association of cholesterol with hepatorenal markers and quality of life in diabetic patients before and after magnesium and potassium supplements.
Cholesterol
Diabetic patients
Magnesium
Potassium
Quality of life
Journal
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
ISSN: 1319-0164
Titre abrégé: Saudi Pharm J
Pays: Saudi Arabia
ID NLM: 9705695
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
09
09
2023
accepted:
04
11
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
Magnesium and potassium are two critical minerals that have been linked to the treatment of diabetes and its consequences. A lack of magnesium has been linked to insulin resistance and diabetes, whereas potassium has been found to promote insulin sensitivity and glucose metabolism. The study aimed to determine the relationship between cholesterol, liver and kidney markers, and quality of life in diabetic patients before and after magnesium and potassium supplementation. It was a single-blind randomized controlled study at Lahore Garrison University and Lahore Medical Research Centre (LMRC). The study included 200 diabetes participants. Four groups were made based on supplements. Blood samples of all diabetes patients were obtained to assess their quality of life before and after using Mg + and K + supplements, as well as the association between cholesterol, liver, and kidney markers. The participants' average age was 51.0 ± 11.08. 139 (69.5 %) of the 200 participants were female, whereas 26 (30.5 %) were male. There was no correlation between the quality of life measure and the patients' cholesterol levels before and after the magnesium and potassium supplementation. Furthermore, the kidney and liver indicators were not dependent on the diabetes individuals' cholesterol levels. The study concluded that none of the four groups noticed a significant effect of magnesium and potassium therapies on the patient's quality of life or cholesterol levels. However, more research is needed to determine if liver and kidney problems are linked to cholesterol levels before and after medication, as the current study found no significant correlation between the two parameters.
Sections du résumé
Background
UNASSIGNED
Magnesium and potassium are two critical minerals that have been linked to the treatment of diabetes and its consequences. A lack of magnesium has been linked to insulin resistance and diabetes, whereas potassium has been found to promote insulin sensitivity and glucose metabolism. The study aimed to determine the relationship between cholesterol, liver and kidney markers, and quality of life in diabetic patients before and after magnesium and potassium supplementation.
Methods
UNASSIGNED
It was a single-blind randomized controlled study at Lahore Garrison University and Lahore Medical Research Centre (LMRC). The study included 200 diabetes participants. Four groups were made based on supplements. Blood samples of all diabetes patients were obtained to assess their quality of life before and after using Mg + and K + supplements, as well as the association between cholesterol, liver, and kidney markers.
Results
UNASSIGNED
The participants' average age was 51.0 ± 11.08. 139 (69.5 %) of the 200 participants were female, whereas 26 (30.5 %) were male. There was no correlation between the quality of life measure and the patients' cholesterol levels before and after the magnesium and potassium supplementation. Furthermore, the kidney and liver indicators were not dependent on the diabetes individuals' cholesterol levels.
Conclusions
UNASSIGNED
The study concluded that none of the four groups noticed a significant effect of magnesium and potassium therapies on the patient's quality of life or cholesterol levels. However, more research is needed to determine if liver and kidney problems are linked to cholesterol levels before and after medication, as the current study found no significant correlation between the two parameters.
Identifiants
pubmed: 38028213
doi: 10.1016/j.jsps.2023.101865
pii: S1319-0164(23)00360-2
pmc: PMC10663893
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101865Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Diabetes. 2002 Jun;51(6):1889-95
pubmed: 12031978
Diabetes Metab. 2005 Dec;31(6):542-50
pubmed: 16357802
Hepatobiliary Surg Nutr. 2015 Apr;4(2):101-8
pubmed: 26005676
Adv Nutr. 2013 May 01;4(3):378S-83S
pubmed: 23674807
Hypertension. 2005 Jan;45(1):18-20
pubmed: 15557387
Diabetes Care. 2009 Sep;32(9):1737-42
pubmed: 19549729
Curr Opin Nephrol Hypertens. 2009 Nov;18(6):526-30
pubmed: 19654543
Appl Environ Microbiol. 2003 Jun;69(6):3152-7
pubmed: 12788710
Am J Nephrol. 2010;31(5):426-34
pubmed: 20389058
Nutrients. 2018 Dec 26;11(1):
pubmed: 30587761
J Am Soc Nephrol. 2002 Mar;13(3):745-753
pubmed: 11856780
Diabetes Care. 2009 Apr;32(4):741-50
pubmed: 19131466
Lancet. 2005 Jan 22-28;365(9456):331-40
pubmed: 15664230
Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):83-91
pubmed: 23402449
J Physiol Biochem. 2016 Mar;72(1):93-106
pubmed: 26634368
Diabetes. 2004 Nov;53(11):2855-60
pubmed: 15504965
World J Gastroenterol. 2012 Aug 7;18(29):3775-81
pubmed: 22876026
Postgrad Med J. 2016 Apr;92(1086):223-34
pubmed: 26842972
Diabet Med. 2005 Sep;22(9):1141-5
pubmed: 16108839
Arch Intern Med. 2001 May 14;161(9):1207-16
pubmed: 11343443
Med Hypotheses. 2000 Sep;55(3):263-5
pubmed: 10985921